ExpreS2ion Biotechnologies - What to look out for in 2024
Together with ExpreS2ion Biotechnologies CEO Bent Frandsen, we took a look at 2023's main achievements and challenges as well as the foundation this has given the company. We also touched upon 2024, focusing on what investors should look out for as the main potential achievements.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 11.45 15 February 2024.
